Product Information:
| Product name |
Tiopronin for Injection |
| Specification |
0.1g |
| Packing |
Customizable |
| Shelf life |
3 Years |
| Standard |
BP. USP. |
| Storage |
Cool and Dry place |
| Sample |
Available |
Indication:
1. It can improve the liver function of acute and chronic hepatitis.
2. For fatty liver, alcoholic liver, drug-induced liver injury and detoxification of heavy metals.
3. It can be used to reduce the adverse reactions of radiotherapy and chemotherapy and prevent the peripheral leucopenia caused by radiotherapy and chemotherapy.
4. For senile early cataract and vitreous opacity.
Adverse reactions:
1. Anaphylactic reaction: in 1569 ADR case reports collected after the launch of tiopronin injection, 115 cases were reported with severe ADR, 79 cases mainly manifested as anaphylactic shock (1 case died). Other adverse reactions included rash, pruritus, nausea, vomiting, fever, shivering, dizziness, palpitation, chest tightness, submandibular gland and parotid gland enlargement, laryngeal edema, dyspnea, allergic reaction, etc.
2. This drug may cause all the adverse reactions of penicillamine, but the incidence of adverse reactions is lower than that of penicillamine.
3. Neutropenia and thrombocytopenia are rare in the blood system. If the peripheral white blood cell count is less than 3.5 × 106 / ml, or the platelet count is less than 10 × 106 / ml, it is recommended to stop the drug.
4. Proteinuria may occur in the urinary system, with an incidence of about 10%. It can be completely recovered soon after drug withdrawal. Another case reported that the drug can cause urine discoloration.
5. The digestive system may have taste loss, abnormal taste, nausea, vomiting, abdominal pain, diarrhea, anorexia, bloating, oral ulcer, etc. It is also reported that cholestasis, liver function test indicators (such as alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase, etc.) rise. If there is any abnormality, the product should be stopped or treated accordingly.
6. Skin reactions are the most common adverse reactions of the drug, with an incidence of about 10% - 32%. The manifestations are skin rash, skin itching, skin redness, urticaria, skin wrinkles, pemphigus, skin and eye yellow staining, etc. skin wrinkles usually occur only after long-term treatment.
7. Respiratory system it is reported that this drug can cause pneumonia, pulmonary hemorrhage and bronchospasm. Other cases reported dyspnea or respiratory distress, as well as bronchiolitis obliterans.
8. Musculoskeletal cases have reported that the use of this drug can cause myasthenia.
9. Long term and extensive use of rare proteinuria or nephrotic syndrome.
10. Others: rare insulin autoimmune syndrome, fatigue and numbness should be stopped.
Taboo:
It is forbidden for the following patients:
1. Patients allergic to the ingredients of this product.
2. Severe hepatitis patients with high jaundice, intractable ascites, gastrointestinal bleeding and other complications.
3. Renal insufficiency with diabetes mellitus.
4. Pregnant and lactating women.
5. Children.
6. Patients with acute severe lead and mercury poisoning.
7. Previous use of this drug had agranulocytosis, aplastic anemia, thrombocytopenia or other serious adverse reactions.
Matters needing attention:
1. Patients with allergic reaction should stop using this drug.
Use with caution for the following patients:
(1) Elderly patients.
(2) Patients with a history of asthma.
(3) The patients who had used penicillamine in the past or had serious adverse reactions when using penicillamine. For patients who have had penicillamine toxicity, the use of this drug should start from a smaller dose.
2. The following tests should be carried out regularly before and after medication to monitor the toxicity of the drug: peripheral blood cell count, platelet count, hemoglobin, plasma albumin, liver function, 24-hour urine protein. In addition, the urine routine should be checked every 3 months or every 6 months.
Audited Supplier 
){kind=link}